• LAST PRICE
    7.9900
  • TODAY'S CHANGE (%)
    Trending Up0.1800 (2.3047%)
  • Bid / Lots
    7.9700/ 3
  • Ask / Lots
    8.0000/ 1
  • Open / Previous Close
    8.0000 / 7.8100
  • Day Range
    Low 7.6850
    High 8.2600
  • 52 Week Range
    Low 1.5700
    High 8.4000
  • Volume
    730,428
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 7.81
TimeVolumeANNX
09:32 ET700888.07
09:34 ET514078.15
09:36 ET758047.83
09:38 ET239697.83
09:39 ET184557.72
09:41 ET191087.7501
09:43 ET337837.8556
09:45 ET287947.91
09:48 ET416617.79
09:50 ET52057.95
09:52 ET222738.1
09:54 ET434928.12
09:56 ET116328.069
09:57 ET68178.085
09:59 ET59618.11
10:01 ET357988.19
10:03 ET107798.2004
10:06 ET251998.19
10:08 ET444708.09
10:10 ET44538
10:12 ET125928.02
10:14 ET44958.02
10:15 ET400808.005
10:17 ET15007.99
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesANNX
Annexon Inc
703.1M
-4.5x
---
United StatesKRRO
Korro Bio Inc
709.3M
-1.0x
---
United StatesNWBO
Northwest Biotherapeutics Inc
714.0M
-10.5x
---
United StatesSVRA
Savara Inc
670.0M
-14.3x
---
United StatesMNMD
Mind Medicine (MindMed) Inc
667.5M
-4.0x
---
United StatesATXS
Astria Therapeutics Inc
746.7M
-5.7x
---
As of 2024-03-28

Company Information

Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is also evaluating ANX005 for the potential treatment of patients with Huntington’s disease (HD). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications.

Contact Information

Headquarters
1400 SIERRA POINT PARKWAY BLDG C SUITE 200BRISBANE, CA, United States 94005
Phone
650-822-5500
Fax
650-636-9773

Executives

Independent Chairman of the Board
Thomas Wiggans
President, Chief Executive Officer, Director
Douglas Love
Chief Financial Officer, Executive Vice President
Jennifer Lew
Executive Vice President, Chief Scientific Officer
Dean Artis
Executive Vice President, Chief Business Officer
Michael Overdorf

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$703.1M
Revenue (TTM)
$0.00
Shares Outstanding
90.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.16
EPS
$-1.78
Book Value
$3.20
P/E Ratio
-4.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.